BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 8259839)

  • 1. [An outline of 5-HT3 receptor antagonists (2)--In clinical applications].
    Tsukagoshi S; Ohta J; Taguchi T
    Gan To Kagaku Ryoho; 1993 Dec; 20(15):2276-81. PubMed ID: 8259839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
    Cunningham RS
    Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting.
    Perez EA
    Cancer J Sci Am; 1998; 4(2):72-7. PubMed ID: 9532406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
    Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
    J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods.
    Mahesh R; Perumal RV; Pandi PV
    Pharmazie; 2005 Feb; 60(2):83-96. PubMed ID: 15739895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Nausea and vomiting].
    Fujii M
    Nihon Rinsho; 2003 Jun; 61(6):954-8. PubMed ID: 12806942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ondansetron, an antagonist of 5-HT3 receptors, in the treatment of antineoplastic drug-induced nausea and vomiting in children.
    Matera MG; Di Tullio M; Lucarelli C; Casale F; Calabria C; Lampa E; Indolfi P; Rossi F
    J Med; 1993; 24(2-3):161-70. PubMed ID: 7691978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?
    Aapro M; Blower P
    Cancer; 2005 Jul; 104(1):1-18. PubMed ID: 15929119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of action of 5-HT3 receptor antagonists: clinical overview and nursing implications.
    Bremerkamp M
    Clin J Oncol Nurs; 2000; 4(5):201-7. PubMed ID: 11111451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Granisetron: an update on its clinical use in the management of nausea and vomiting.
    Aapro M
    Oncologist; 2004; 9(6):673-86. PubMed ID: 15561811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An overview of ondansetron for chemotherapy-induced nausea and emesis.
    San Angel F
    J Intraven Nurs; 1993; 16(2):84-9. PubMed ID: 8478782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prophylaxis of chemotherapy-induced vomiting and nausea].
    Tóth J; Szántó J
    Magy Onkol; 2008 Dec; 52(4):391-4. PubMed ID: 19068468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
    Slabý J; Trnený M; Procházka B; Klener P
    Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is ondansetron more effective than granisetron for chemotherapy-induced nausea and vomiting? A review of comparative trials.
    Vrabel M
    Clin J Oncol Nurs; 2007 Dec; 11(6):809-13. PubMed ID: 18063539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of postoperative nausea and vomiting with ondansetron in patients administered anti-neoplastic agents].
    Morimoto Y; Nakamura M; Tamura T; Kunii T; Shimizu K; Miyauchi Y
    Masui; 1996 Sep; 45(9):1096-9. PubMed ID: 8905945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of ondansetron and granisetron on chemotherapy-induced emesis in adults: the need for comparative pharmacoeconomic data.
    Hedayati S; Moatti JP; Seitz JF
    Clin Ther; 1994; 16(3):569-80. PubMed ID: 7923321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron].
    Mabro M; Granisétron PK
    Bull Cancer; 1999 Mar; 86(3):295-301. PubMed ID: 10210764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.